Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking ...
Ziarul BURSA | BURSA.RO5h
BioAge wants to raise $158 million through IPO
BioAge Labs Inc., an American clinical-stage biotech company developing therapies for obesity and metabolic diseases, is ...
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M ...
Obesity drug developer BioAge seeks up to $587 million valuation in US IPO
Healthcare firms have done comparatively well in an otherwise subdued U.S. IPO market in 2024, which analysts touted as a comeback year for public offerings. The Richmond, California-based company ...
Yahoo3d
Obesity drug developer BioAge seeks up to $587 million valuation in US IPO
(Reuters) - Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a ...